Abstract
Purpose
The aim of this systematic review is to summarize the current knowledge about the etiology and pathogenesis of borderline tumors ovarian cancer with special emphasis on the role of endocrine treatments and reproductive factors to establish a foundation for future studies.
Methods
We performed a systematic review on the relation between ovarian epithelial tumors (OET) and reproductive factors using the keywords: ovarian cancer, ovarian tumor, ovarian borderline tumor, age at menarche, age at menopause, parity, infertility, PCO syndrome, oral contraception, menopausal hormone therapy, fertility treatment. Totally, 3,290 abstracts were scanned for their relevance in this publication and 127 were finally included.
Results
The incidence of ovarian epithelial cancer and ovarian borderline tumors is influenced by certain reproductive factors. The strongest protective effects are conferred by parity and use of oral contraceptive pills. Recent molecular biologic and histopathologic studies prove that OET represent a diverse group of tumors, each histologic type with a different genetic background. This is at least partly reflected in epidemiologic and clinical studies showing different risk modulating effects of reproductive factors and endocrine therapies on OET.
Conclusions
The etiology and pathogenesis of ovarian cancer are still not fully understood. None of the so far proposed hypothesis on the development of OET can fully account for the epidemiologic and clinical findings in the context of reproductive factors and OET development. Further research approaches are warranted and need to put more weight on the clinical and genetical diversity of OET to yield a more detailed insight into their pathogenesis.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138
Gershenson DM (2002) Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 16(4):513–527. pii: S1521693402903081
Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65(22):10602–10612. doi:10.1158/0008-5472.CAN-05-2240
Tsai HW, Ko CC, Yeh CC, Chen YJ, Twu NF, Chao KC, Yen MS (2011) Unilateral salpingo-oophorectomy as fertility-sparing surgery for borderline ovarian tumors. J Chin Med Assoc 74(6):250–254. doi:10.1016/j.jcma.2011.04.003
Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, Devesa S (2004) Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100(5):1045–1052. doi:10.1002/cncr.20080
Kurman RJ, Shih Ie M (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 42(7):918–931. doi:10.1016/j.humpath.2011.03.003
Burks RT, Sherman ME, Kurman RJ (1996) Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 20(11):1319–1330
Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28(4):496–504. pii: 00000478-200404000-00009
Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, Malpica A, Stoler MH, Kurman RJ (2004) Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35(8):934–948. pii: S0046817704001546
Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C (1998) Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 83(10):2157–2163. doi:10.1002/(SICI)1097-0142(19981115)83:10<2157:AID-CNCR14>3.0.CO;2-D
Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160(4):1223–1228. pii: S0002-9440(10)62549-7
Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484–486
Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M (2004) Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 64(19):6915–6918. doi:10.1158/0008-5472.CAN-04-2067
Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer MJ, deFazio A, Chenevix-Trench G, Bowtell DD (2008) Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 6(11):1678–1690. doi:10.1158/1541-7786.MCR-08-0193
Integrated genomic analyses of ovarian carcinoma (2011). Nature 474 (7353):609-615. doi:10.1038/nature10166
Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221(1):49–56. doi:10.1002/path.2696
Chen HH, Wang YC, Fann MJ (2006) Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol Cell Biol 26(7):2736–2745. doi:10.1128/MCB.26.7.2736-2745.2006
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069–1075. doi:10.1038/nature07423
Aldred MA, Trembath RC (2000) Activating and inactivating mutations in the human GNAS1 gene. Hum Mutat 16(3):183–189. doi:10.1002/1098-1004(200009)16:3<183:AID-HUMU1>3.0.CO;2-L
Kelemen LE, Kobel M (2011) Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol 12(11):1071–1080. doi:10.1016/S1470-2045(11)70058-4
Hart WR (2005) Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 24(1):4–25. pii: 00004347-200501000-00003
Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM (1991) K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139(4):777–785
Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90(2):378–381. pii: S0090825803002646
Mayr D, Hirschmann A, Lohrs U, Diebold J (2006) KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 103(3):883–887. doi:10.1016/j.ygyno.2006.05.029
Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao SW (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53(7):1489–1492
Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M (2008) Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198(4):351–356. doi:10.1016/j.ajog.2008.01.005
Landen CN Jr, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6):995–1005. doi:10.1200/JCO.2006.07.9970
Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih Ie M (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174(5):1597–1601. doi:10.2353/ajpath.2009.081000
Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O (2011) PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 225(2):189–194. doi:10.1002/path.2940
Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O (2011) Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. doi:10.1038/modpathol.2011.189
Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O (2011) Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol 24(8):1146–1155. doi:10.1038/modpathol.2011.70
Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, Glas R, Ma MJ, Kurman RJ, Shih Ie M, Wang TL (2010) DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 16(7):1997–2008. doi:10.1158/1078-0432.CCR-09-2105
Wu R, Zhai Y, Fearon ER, Cho KR (2001) Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61(22):8247–8255
Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, Palacios J (2001) Beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 10(2):116–122
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih Ie M, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363(16):1532–1543. doi:10.1056/NEJMoa1008433
Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58(10):2095–2097
Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H, Isonishi S, Yasuhara T, Yoshimura T, Ohtake Y, Ochiai K, Yokota J, Tanaka T (2000) Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 85(2):160–165. doi:10.1002/(SICI)1097-0215(20000115)85:2<160:AID-IJC2>3.0.CO;2-5
Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60(24):7052–7056
Prowse AH, Manek S, Varma R, Liu J, Godwin AK, Maher ER, Tomlinson IP, Kennedy SH (2006) Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 119(3):556–562. doi:10.1002/ijc.21845
Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63–70. doi:10.1038/nm1173
Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3 K/Pten signaling pathways. Cancer Cell 11(4):321–333. doi:10.1016/j.ccr.2007.02.016
Kang SK, Choi KC, Cheng KW, Nathwani PS, Auersperg N, Leung PC (2000) Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 141(1):72–80
Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R (1989) Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25(2):215–221
Emons G, Ortmann O, Pahwa GS, Hackenberg R, Oberheuser F, Schulz KD (1992) Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer. Acta Obstet Gynecol Scand Suppl 155:31–38
Irmer G, Burger C, Muller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz KD, Emons G (1995) Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55(4):817–822
So WK, Cheng JC, Poon SL, Leung PC (2008) Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J 275(22):5496–5511. doi:10.1111/j.1742-4658.2008.06679.x
Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD, Schally AV (1993) High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53(22):5439–5446
Emons G, Pahwa GS, Ortmann O, Knuppen R, Oberheuser F, Schulz KD (1990) LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview. J Steroid Biochem Mol Biol 37(6):1003–1006. pii: 0960-0760(90)90457-V
Emons G, Weiss S, Ortmann O, Grundker C, Schulz KD (2000) LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol 142(6):665–670. doi:10.1530/eje.0.1420665
Ling Poon S, Lau MT, Hammond GL, Leung PC (2011) Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells. Endocrinology 152(3):764–772. doi:10.1210/en.2010-0942
Zheng W, Magid MS, Kramer EE, Chen YT (1996) Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 148(1):47–53
Bose CK (2008) Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer. Oncol Res 17(5):231–238
Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK (2001) Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 172(1–2):213–222. pii: S0303-7207(00)00340-3
Lu JJ, Zheng Y, Kang X, Yuan JM, Lauchlan SC, Pike MC, Zheng W (2000) Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol 79(2):158–168. doi:10.1006/gyno.2000.5928
Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B (2004) Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch Gynecol Obstet 270(3):151–156. doi:10.1007/s00404-003-0519-4
Mandai M, Konishi I, Kuroda H, Fukumoto M, Komatsu T, Yamamoto S, Nanbu K, Rao CV, Mori T (1997) Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur J Cancer 33(9):1501–1507. pii: S0959804997001664
Tourgeman DE, Lu JJ, Boostanfar R, Amezcua C, Felix JC, Paulson RJ (2002) Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro. Fertil Steril 78(5):1096–1099. pii: S0015028202033678
Choi JH, Choi KC, Auersperg N, Leung PC (2004) Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 89(11):5508–5516. doi:10.1210/jc.2004-0044
Tashiro H, Katabuchi H, Begum M, Li X, Nitta M, Ohtake H, Okamura H (2003) Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage-dependent and -independent growth in human ovarian surface epithelial cell lines. Cancer Sci 94(11):953–959
Ji Q, Liu PI, Chen PK, Aoyama C (2004) Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 112(5):803–814. doi:10.1002/ijc.20478
Lau MT, Wong AS, Leung PC (2010) Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology 151(7):2985–2993. doi:10.1210/en.2009-1318
Schiffenbauer YS, Meir G, Maoz M, Even-Ram SC, Bar-Shavit R, Neeman M (2002) Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin. Gynecol Oncol 84(2):296–302. doi:10.1006/gyno.2001.6512
Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Munstedt K, Rao CV, Lang U, Preissner KT (2002) Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 87(11):5290–5296
Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W (2002) VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 97(2):163–167. doi:10.1002/ijc.1593
Basille C, Olivennes F, Le Calvez J, Beron-Gaillard N, Meduri G, Lhomme C, Duvillard P, Benard J, Morice P (2006) Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours. Hum Reprod 21(12):3241–3245. doi:10.1093/humrep/del301
Heinonen PK, Koivula T, Rajaniemi H, Pystynen P (1986) Peripheral and ovarian venous concentrations of steroid and gonadotropin hormones in postmenopausal women with epithelial ovarian tumors. Gynecol Oncol 25(1):1–10
Cunat S, Rabenoelina F, Daures JP, Katsaros D, Sasano H, Miller WR, Maudelonde T, Pujol P (2005) Aromatase expression in ovarian epithelial cancers. J Steroid Biochem Mol Biol 93(1):15–24. doi:10.1016/j.jsbmb.2004.10.021
Brandenberger AW, Tee MK, Jaffe RB (1998) Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 83(3):1025–1028
Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H (1992) Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 75(6):1497–1502
Song J, Fadiel A, Edusa V, Chen Z, So J, Sakamoto H, Fishman DA, Naftolin F (2005) Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett 220(1):57–65. doi:10.1016/j.canlet.2004.04.024
Keith Bechtel M, Bonavida B (2001) Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecol Oncol 82(1):127–138. doi:10.1006/gyno.2001.6221
Bai W, Oliveros-Saunders B, Wang Q, Acevedo-Duncan ME, Nicosia SV (2000) Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cell Dev Biol Anim 36(10):657–666. doi:10.1290/1071-2690(2000)036<0657:ESOOSE>2.0.CO;2
Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM (2001) Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61(18):6768–6776
Bardin A, Moll F, Margueron R, Delfour C, Chu ML, Maudelonde T, Cavailles V, Pujol P (2005) Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 146(2):760–768. doi:10.1210/en.2004-1239
Yousef GM, Diamandis EP (2002) Kallikreins, steroid hormones and ovarian cancer: is there a link? Minerva Endocrinol 27(3):157–166
Simpson BJ, Langdon SP, Rabiasz GJ, Macleod KG, Hirst GL, Bartlett JM, Crew AJ, Hawkins RA, Macineira-Perez PP, Smyth JF, Miller WR (1998) Estrogen regulation of transforming growth factor-alpha in ovarian cancer. J Steroid Biochem Mol Biol 64(3–4):137–145. pii: S0960-0760(97)00159-3
Wimalasena J, Meehan D, Dostal R, Foster JS, Cameron M, Smith M (1993) Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncol Res 5(8):325–337
Krywicki RF, Figueroa JA, Jackson JG, Kozelsky TW, Shimasaki S, Von Hoff DD, Yee D (1993) Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. Eur J Cancer 29A(14):2015–2019
Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O (2007) Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193(3):421–433. doi:10.1677/JOE-07-0087
Mukherjee K, Syed V, Ho SM (2005) Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene 24(27):4388–4400. doi:10.1038/sj.onc.1208623
Kang SK, Choi KC, Tai CJ, Auersperg N, Leung PC (2001) Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. Endocrinology 142(2):580–588
Treeck O, Haldar C, Ortmann O (2006) Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol Rep 15(1):231–235
Abu-Jawdeh GM, Jacobs TW, Niloff J, Cannistra SA (1996) Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol 60(2):301–307. doi:10.1006/gyno.1996.0043
Ho SM (2003) Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 1:73. doi:10.1186/1477-7827-1-73
Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G, Darai E (2006) Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep 15(4):743–748
Syed V, Mukherjee K, Godoy-Tundidor S, Ho SM (2007) Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 102(2):442–452. doi:10.1002/jcb.21304
Hua K, Feng W, Cao Q, Zhou X, Lu X, Feng Y (2008) Estrogen and progestin regulate metastasis through the PI3 K/AKT pathway in human ovarian cancer. Int J Oncol 33(5):959–967
Peluso JJ (2011) Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer. Steroids 76(9):903–909. doi:10.1016/j.steroids.2011.02.011
Takahashi A, Kato K, Kuboyama A, Inoue T, Tanaka Y, Kuhara A, Kinoshita K, Takeda S, Wake N (2009) Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells. Gynecol Oncol 113(2):270–276. doi:10.1016/j.ygyno.2008.12.032
Gabra H, Langdon SP, Watson JE, Hawkins RA, Cohen BB, Taylor L, Mackay J, Steel CM, Leonard RC, Smyth JF (1995) Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer. Clin Cancer Res 1(9):945–953
Davis M, Hitchcock A, Foulkes WD, Campbell IG (1996) Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 56(4):741–744
Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J (2013) Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 23(1):25–33. doi:10.1097/IGC.0b013e3182788466
Murdoch WJ, Van Kirk EA, Isaak DD, Shen Y (2008) Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts. Gynecol Oncol 110(2):251–255. doi:10.1016/j.ygyno.2008.03.021
Peluso JJ, Gawkowska A, Liu X, Shioda T, Pru JK (2009) Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology 150(11):4846–4854. doi:10.1210/en.2009-0730
Romero-Sanchez M, Peiper SC, Evans B, Wang Z, Catasus L, Ribe A, Prat J, Giri JG (2008) Expression profile of heptahelical putative membrane progesterone receptors in epithelial ovarian tumors. Hum Pathol 39(7):1026–1033. doi:10.1016/j.humpath.2007.11.007
Peluso JJ (2006) Multiplicity of progesterone’s actions and receptors in the mammalian ovary. Biol Reprod 75(1):2–8. doi:10.1095/biolreprod.105.049924
Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, Castagna G (1998) Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 17(2):231–237
Edmondson RJ, Monaghan JM, Davies BR (2002) The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 86(6):879–885. doi:10.1038/sj.bjc.6600154
Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94(7):3320–3323
Li AJ, Elmore RG, Pavelka JC, Karlan BY (2007) Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecol Oncol 107(3):420–423. doi:10.1016/j.ygyno.2007.07.059
Evangelou A, Jindal SK, Brown TJ, Letarte M (2000) Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 60(4):929–935
Sheach LA, Adeney EM, Kucukmetin A, Wilkinson SJ, Fisher AD, Elattar A, Robson CN, Edmondson RJ (2009) Androgen-related expression of G-proteins in ovarian cancer. Br J Cancer 101(3):498–503. doi:10.1038/sj.bjc.6605153
Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B (1997) Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 66(2):250–254. doi:10.1006/gyno.1997.4764
Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 2(7716):163
Schildkraut JM, Bastos E, Berchuck A (1997) Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 89(13):932–938
Kuhn E, Kurman RJ, Shih IM (2012) Ovarian cancer is an imported disease: fact or fiction? Curr Obstet Gynecol Rep 1(1):1–9. doi:10.1007/s13669-011-0004-1
Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM (2012) High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 109(10):3921–3926. doi:10.1073/pnas.1117135109
Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R (2010) Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 34(10):1407–1416. doi:10.1097/PAS.0b013e3181ef7b16
Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih Ie M (2012) TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma–evidence supporting the clonal relationship of the two lesions. J Pathol 226(3):421–426. doi:10.1002/path.3023
Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr, Lu KH (2005) Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11(17):6116–6126. doi:10.1158/1078-0432.CCR-04-2509
Murdoch WJ, Martinchick JF (2004) Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood) 229(6):546–552
Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71(4):717–721
Biskind GR, Biskind MS (1948) Atrophy of ovaries transplanted to the spleen in unilaterally castrated rats; proliferative changes following subsequent removal of intact ovary. Science 108(2797):137–138. doi:10.1126/science.108.2797.137
Blaakaer J, Baeksted M, Micic S, Albrectsen P, Rygaard J, Bock J (1995) Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. Biol Reprod 53(4):775–779
Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW (1976) Hormonal profiles after the menopause. Br Med J 2(6039):784–787
Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90(23):1774–1786
Silva EG, Tornos C, Fritsche HA Jr, el-Naggar A, Gray K, Ordonez NG, Luna M, Gershenson D (1997) The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 10(9):879–883
Nishizuka Y, Sakakura T, Tsujimura T, Matsumoto K (1973) Steroid biosynthesis in vitro by dysgenetic ovaries induced by neonatal thymectomy in mice. Endocrinology 93(4):786–792
Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW (1995) Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274(24):1926–1930
Wynder EL, Dodo H, Barber HR (1969) Epidemiology of cancer of the ovary. Cancer 23(2):352–370
Sonnichsen AC, Lindlacher U, Richter WO, Schwandt P (1990) Obesity, body fat distribution and the incidence of breast, cervical, endometrial and ovarian carcinomas. Dtsch Med Wochenschr 115(50):1906–1910. doi:10.1055/s-2008-1065242
Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies (2012). PLoS Med 9(4):e1001200. doi:10.1371/journal.pmed.1001200
Olsen CM, Green AC, Nagle CM, Jordan SJ, Whiteman DC, Bain CJ, Webb PM (2008) Epithelial ovarian cancer: testing the ‘androgens hypothesis’. Endocr Relat Cancer 15(4):1061–1068. doi:10.1677/ERC-08-0075
Kotsopoulos J, Baer HJ, Tworoger SS (2010) Anthropometric measures and risk of epithelial ovarian cancer: results from the nurses’ health study. Obesity (Silver Spring) 18(8):1625–1631. doi:10.1038/oby.2009.461
Lahmann PH, Cust AE, Friedenreich CM, Schulz M, Lukanova A, Kaaks R, Lundin E, Tjonneland A, Halkjaer J, Severinsen MT, Overvad K, Fournier A, Chabbert-Buffet N, Clavel-Chapelon F, Dossus L, Pischon T, Boeing H, Trichopoulou A, Lagiou P, Naska A, Palli D, Grioni S, Mattiello A, Tumino R, Sacerdote C, Redondo ML, Jakszyn P, Sanchez MJ, Tormo MJ, Ardanaz E, Arriola L, Manjer J, Jirstrom K, Bueno-de-Mesquita HB, May AM, Peeters PH, Onland-Moret NC, Bingham S, Khaw KT, Allen NE, Spencer E, Rinaldi S, Slimani N, Chajes V, Michaud D, Norat T, Riboli E (2010) Anthropometric measures and epithelial ovarian cancer risk in the European prospective investigation into cancer and nutrition. Int J Cancer 126(10):2404–2415. doi:10.1002/ijc.24952
Rinaldi S, Dossus L, Lukanova A, Peeters PH, Allen NE, Key T, Bingham S, Khaw KT, Trichopoulos D, Trichopoulou A, Oikonomou E, Pera G, Larranaga N, Martinez-Garcia C, Ardanaz E, Quiros JR, Tormo MJ, Tjonneland A, Olsen A, Overvad K, Chang-Claude J, Linseisen J, Schulz M, Boeing H, van Gils CH, Bueno-de-Mesquita BH, Pala V, Palli D, Panico S, Tumino R, Vineis P, Clavel-Chapelon F, Mesrine S, Boutron-Ruault MC, Lundin E, Agren A, Berglund G, Manjer J, Kumle M, Lund E, Slimani N, Saracci R, Riboli E, Kaaks R (2007) Endogenous androgens and risk of epithelial ovarian cancer: results from the European prospective investigation into cancer and nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 16(1):23–29. doi:10.1158/1055-9965.EPI-06-0755
Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, Nomura AM, Terada KY, Carney ME, Sobin LH (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158(7):629–638
Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, Lund E, Fournier A, Overvad K, Hansen L, Tjonneland A, Fedirko V, Rinaldi S, Romieu I, Clavel-Chapelon F, Engel P, Kaaks R, Schutze M, Steffen A, Bamia C, Trichopoulou A, Zylis D, Masala G, Pala V, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodriguez L, Travier N, Sanchez MJ, Huerta JM, Ardanaz E, Larranaga N, Jirstrom K, Manjer J, Idahl A, Ohlson N, Khaw KT, Wareham N, Mouw T, Norat T, Riboli E (2011) Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 105(9):1436–1442. doi:10.1038/bjc.2011.371
Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL (2012) Age at menarche and risk of ovarian cancer: A meta-analysis of epidemiological studies. Int J Cancer. doi:10.1002/ijc.27952
Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, Kjaer SK (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16(6):1160–1166. doi:10.1158/1055-9965.EPI-07-0089
Braem MG, Onland-Moret NC, van den Brandt PA, Goldbohm RA, Peeters PH, Kruitwagen RF, Schouten LJ (2010) Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 172(10):1181–1189. doi:10.1093/aje/kwq264
Pelucchi C, Galeone C, Talamini R, Bosetti C, Montella M, Negri E, Franceschi S, LaVecchia C (2007) Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol 196(1):83 e81–e87. doi:10.1016/j.ajog.2006.06.088
Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, Conti E, Montella M, La Vecchia C (2001) Reproductive and hormonal factors and ovarian cancer. Ann Oncol 12(3):337–341
Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C (1993) Risk factors for epithelial ovarian cancer in women under age 45. Eur J Cancer 29A(9):1297–1301
Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR (2002) Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 156(4):363–373
Chiaffarino F, Pelucchi C, Negri E, Parazzini F, Franceschi S, Talamini R, Montella M, Ramazzotti V, La Vecchia C (2005) Breastfeeding and the risk of epithelial ovarian cancer in an Italian population. Gynecol Oncol 98(2):304–308. doi:10.1016/j.ygyno.2005.05.006
Booth M, Beral V, Smith P (1989) Risk factors for ovarian cancer: a case-control study. Br J Cancer 60(4):592–598
Jordan SJ, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA (2012) Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control 23(6):919–927. doi:10.1007/s10552-012-9963-4
Titus-Ernstoff L, Rees JR, Terry KL, Cramer DW (2010) Breast-feeding the last born child and risk of ovarian cancer. Cancer Causes Control 21(2):201–207. doi:10.1007/s10552-009-9450-8
Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC (2008) Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer 44(16):2477–2484. doi:10.1016/j.ejca.2008.07.009
Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE (2007) Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control 18(5):517–523. doi:10.1007/s10552-007-0130-2
Siskind V, Green A, Bain C, Purdie D (1997) Breastfeeding, menopause, and epithelial ovarian cancer. Epidemiology 8(2):188–191
Rosenblatt KA, Thomas DB (1993) Lactation and the risk of epithelial ovarian cancer. The WHO collaborative study of neoplasia and steroid contraceptives. Int J Epidemiol 22(2):192–197
Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM (1983) Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 117(2):128–139
Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative ovarian cancer group. Am J Epidemiol 136(10):1184–1203
Jordan SJ, Siskind V, A CG, Whiteman DC, Webb PM (2010) Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control 21(1):109–116. doi:10.1007/s10552-009-9440-x
Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER (2001) Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 84(5):714–721. doi:10.1054/bjoc.2000.1596
Mills PK, Riordan DG, Cress RD (2004) Epithelial ovarian cancer risk by invasiveness and cell type in the central valley of California. Gynecol Oncol 95(1):215–225. doi:10.1016/j.ygyno.2004.07.012
Gates MA, Rosner BA, Hecht JL, Tworoger SS (2010) Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 171(1):45–53. doi:10.1093/aje/kwp314
Purdie DM, Siskind V, Bain CJ, Webb PM, Green AC (2001) Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 153(9):860–864
McNeilly AS (2001) Lactational control of reproduction. Reprod Fertil Dev 13(7–8):583–590
Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A, Janson PO (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344(8932):1250–1254. pii: S0140-6736(94)90749-8
Risch HA, Marrett LD, Howe GR (1994) Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 140(7):585–597
Liu Q, Lambe M, Baik I, Cnattingius S, Riman T, Ekbom A, Adami HO, Hsieh CC (2006) A prospective study of the transient decrease in ovarian cancer risk following childbirth. Cancer Epidemiol Biomarkers Prev 15(12):2508–2513. doi:10.1158/1055-9965.EPI-06-0242
Hinkula M, Pukkala E, Kyyronen P, Kauppila A (2006) Incidence of ovarian cancer of grand multiparous women–a population-based study in Finland. Gynecol Oncol 103(1):207–211. doi:10.1016/j.ygyno.2006.02.025
Whiteman DC, Murphy MF, Cook LS, Cramer DW, Hartge P, Marchbanks PA, Nasca PC, Ness RB, Purdie DM, Risch HA (2000) Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst 92(14):1172–1177
Albrektsen G, Heuch I, Kvale G (1996) Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study. Cancer Causes Control 7(4):421–427
Chen MT, Cook LS, Daling JR, Weiss NS (1996) Incomplete pregnancies and risk of ovarian cancer (Washington, United States). Cancer Causes Control 7(4):415–420
Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N, Quinn M, Wright G, Russell P, Susil B (1995) Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of women’s health study group. Int J Cancer 62(6):678–684
Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE (1995) A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76(2):284–290
Bernal A, Mendez-Moran L, Fajardo-Gutierrez A, Gonzalez-Lira G, Escudero P, Ortiz H (1995) Univariate and multivariate analysis of risk factors for ovarian cancer: case-control study. Mexico City. Arch Med Res 26(3):245–249
Lund E (1992) Mortality from ovarian cancer among women with many children. Int J Epidemiol 21(5):872–876
Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR (2001) Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 83(3):575–585. doi:10.1006/gyno.2001.6451
Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR (1988) Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 48(20):5849–5852
Harris R, Whittemore AS, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative ovarian cancer group. Am J Epidemiol 136(10):1204–1211
Parazzini F, Restelli C, La Vecchia C, Negri E, Chiari S, Maggi R, Mangioni C (1991) Risk factors for epithelial ovarian tumours of borderline malignancy. Int J Epidemiol 20(4):871–877
Merrill RM, Fugal S, Novilla LB, Raphael MC (2005) Cancer risk associated with early and late maternal age at first birth. Gynecol Oncol 96(3):583–593. doi:10.1016/j.ygyno.2004.11.038
Risch HA, Marrett LD, Jain M, Howe GR (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144(4):363–372
Kvale G, Heuch I, Nilssen S, Beral V (1988) Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 42(2):246–251
Kurian AW, Balise RR, McGuire V, Whittemore AS (2005) Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 96(2):520–530. doi:10.1016/j.ygyno.2004.10.037
Jordan SJ, Green AC, Nagle CM, Olsen CM, Whiteman DC, Webb PM (2009) Beyond parity: association of ovarian cancer with length of gestation and offspring characteristics. Am J Epidemiol 170(5):607–614. doi:10.1093/aje/kwp185
Brinton LA, Melton LJ 3rd, Malkasian GD Jr, Bond A, Hoover R (1989) Cancer risk after evaluation for infertility. Am J Epidemiol 129(4):712–722
Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B (1998) Cancer incidence in a cohort of infertile women. Am J Epidemiol 147(11):1038–1042
Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A (1999) Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 71(5):853–859. pii: S0015-0282(99)00085-0
Venn A, Watson L, Bruinsma F, Giles G, Healy D (1999) Risk of cancer after use of fertility drugs with in vitro fertilisation. Lancet 354(9190):1586–1590. doi:10.1016/S0140-6736(99)05203-4
Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH (2002) Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155(3):217–224
Rodriguez C, Tatham LM, Calle EE, Thun MJ, Jacobs EJ, Heath CW Jr (1998) Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control 9(6):645–651
Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG (2004) A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 160(11):1070–1078. doi:10.1093/aje/kwh315
Jensen A, Sharif H, Olsen JH, Kjaer SK (2008) Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol 168(1):49–57. doi:10.1093/aje/kwn094
Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE (2007) Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 166(8):894–901. doi:10.1093/aje/kwm157
Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL (2004) Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 103(6):1194–1203. doi:10.1097/01.AOG.0000128139.92313.74
Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL (2004) Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 82(2):405–414. doi:10.1016/j.fertnstert.2004.02.109
Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(4):385–394. doi:10.1016/S1470-2045(11)70404-1
Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C (1996) Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88(4 Pt 1):554–559
Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S (2009) Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 19(3):398–405
Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F (1976) Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 57(5):1320–1329. doi:10.1172/JCI108400
Baird DT, Corker CS, Davidson DW, Hunter WM, Michie EA, Van Look PF (1977) Pituitary-ovarian relationships in polycystic ovary syndrome. J Clin Endocrinol Metab 45(4):798–801
Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ (2007) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 335(7621):651. doi:10.1136/bmj.39289.649410.55
Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB (2011) Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol 21(3):188–196. doi:10.1016/j.annepidem.2010.10.002
Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L (2010) Hormonal contraception and risk of cancer. Hum Reprod Update 16(6):631–650. doi:10.1093/humupd/dmq022
Grimbizis GF, Tarlatzis BC (2010) The use of hormonal contraception and its protective role against endometrial and ovarian cancer. Best Pract Res Clin Obstet Gynaecol 24(1):29–38. doi:10.1016/j.bpobgyn.2009.08.010
Lurie G, Thompson P, McDuffie KE, Carney ME, Terada KY, Goodman MT (2007) Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol 109(3):597–607. doi:10.1097/01.AOG.0000255664.48970.e6
Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL, Harlap S, Shapiro S (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139(7):654–661
Walker GR, Schlesselman JJ, Ness RB (2002) Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 186(1):8–14. pii: S0002937802860628
Ness RB, Grisso JA, Vergona R, Klapper J, Morgan M, Wheeler JE (2001) Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 12(3):307–312
Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G (1999) Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners’ oral contraception study. BMJ 318(7176):96–100
Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL (1990) Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 43(6):559–568. pii: 0895-4356(90)90160-Q
Rosenberg L, Shapiro S, Slone D, Kaufman DW, Helmrich SP, Miettinen OS, Stolley PD, Rosenshein NB, Schottenfeld D, Engle RL Jr (1982) Epithelial ovarian cancer and combination oral contraceptives. JAMA 247(23):3210–3212
Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609):303–314. doi:10.1016/S0140-6736(08)60167-1
Parazzini F, Chiaffarino F, Negri E, Surace M, Benzi G, Franceschi S, Fedele L, La Vecchia C (2004) Risk factors for different histological types of ovarian cancer. Int J Gynecol Cancer 14(3):431–436. doi:10.1111/j.1048-891x.2004.14302.x
Wittenberg J, Cook LS, Rossing MA, Weiss NS (1999) Reproductive risk factors for mucinous and non-mucinous epithelial ovarian cancer. Epidemiology 10(6):761–763
Siskind V, Green A, Bain C, Purdie D (2000) Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 11(2):106–110
Riman T, Nilsson S, Persson IR (2004) Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 83(9):783–795. doi:10.1111/j.0001-6349.2004.00550.x
Bosetti C, Negri E, Franceschi S, Trichopoulos D, Beral V, La Vecchia C (2001) Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 285 (24):3089; author reply 3090. pii: jlt0627-2
Garg PP, Kerlikowske K, Subak L, Grady D (1998) Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92(3):472–479. pii: S0029-7844(98)00139-2
Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288(3):334–341. pii: joc20074
Negri E, Tzonou A, Beral V, Lagiou P, Trichopoulos D, Parazzini F, Franceschi S, Booth M, La Vecchia C (1999) Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 80(6):848–851. doi:10.1002/(SICI)1097-0215(19990315)80:6<848:AID-IJC8>3.0.CO;2-E
Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR (2002) Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94(7):497–504
Ortmann O, Doren M, Windler E (2011) Hormone therapy in perimenopause and postmenopause (HT). Interdisciplinary S3 Guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet 284(2):343–355. doi:10.1007/s00404-011-1878-x
Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck A, Danforth KN, Park Y, Brinton LA (2012) Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer 107(7):1181–1187. doi:10.1038/bjc.2012.397
Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, Bock JE, Blaakaer J (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164(20):2253–2259. doi:10.1001/archinte.164.20.2253
Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 290(13):1739–1748. doi:10.1001/jama.290.13.1739
Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285(11):1460–1465. pii: joc01947
Greiser CM, Greiser EM, Doren M (2007) Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 13(5):453–463. doi:10.1093/humupd/dmm012
Beral V, Bull D, Green J, Reeves G (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369(9574):1703–1710. doi:10.1016/S0140-6736(07)60534-0
Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 16(12):2548–2556. doi:10.1158/1055-9965.EPI-07-0550
Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV (2010) Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen. Int J Cancer 127(12):2928–2935. doi:10.1002/ijc.25515
Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, Hartge P (2006) Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98(19):1397–1405. doi:10.1093/jnci/djj375
Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, Wang B (2008) Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 108(3):641–651. doi:10.1016/j.ygyno.2007.12.003
Pearce CL, Chung K, Pike MC, Wu AH (2009) Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115(3):531–539. doi:10.1002/cncr.23956
Tsilidis KK, Allen NE, Key TJ, Dossus L, Kaaks R, Bakken K, Lund E, Fournier A, Dahm CC, Overvad K, Hansen L, Tjonneland A, Rinaldi S, Romieu I, Boutron-Ruault MC, Clavel-Chapelon F, Lukanova A, Boeing H, Schutze M, Benetou V, Palli D, Berrino F, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodriguez L, Duell EJ, Sanchez MJ, Huerta JM, Ardanaz E, Amiano P, Khaw KT, Wareham N, Riboli E (2011) Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 22(8):1075–1084. doi:10.1007/s10552-011-9782-z
Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O (2009) Hormone therapy and ovarian cancer. JAMA 302(3):298–305. doi:10.1001/jama.2009.1052
Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, Quinn MA, Green AC (1999) Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81(3):559–563. doi:10.1038/sj.bjc.6690731
Risch HA (1996) Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 63(2):254–257. doi:10.1006/gyno.1996.0315
Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, Hartge P, Hollenbeck A, Park Y, Wentzensen N (2012) Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer 131(4):938–948. doi:10.1002/ijc.26469
Matei MC, Caruntu ID, Negura L, Petrariu FD, Ifrim S, Acatrinei L, Sulugiuc A, Azoicai D (2010) The assessment of relations between main histologic type of ovarian cancer and some risk and prognostic factors. Rev Med Chir Soc Med Nat Iasi 114(4):1135–1141
Mills PK, Riordan DG, Cress RD, Goldsmith DF (2005) Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 29(2):124–132. doi:10.1016/j.cdp.2004.11.002
Morch LS, Lokkegaard E, Andreasen AH, Kjaer SK, Lidegaard O (2012) Hormone therapy and ovarian borderline tumors: a national cohort study. Cancer Causes Control 23(1):113–120. doi:10.1007/s10552-011-9860-2
Martinez F, Manubens M, Carreras O, Tur R, Barri PN (1993) Ovarian function during hormonal replacement therapy in perimenopausal women. Adv Contracept 9(1):71–74
Gebbie AE, Glasier A, Sweeting V (1995) Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Contraception 52(4):221–222. pii: 001078249500184C
Waaseth M, Bakken K, Dumeaux V, Olsen KS, Rylander C, Figenschau Y, Lund E (2008) Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort—a cross-sectional analysis. BMC Womens Health 8:1. doi:10.1186/1472-6874-8-1
Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG (1994) Ovarian tumors in a cohort of infertile women. N Engl J Med 331(12):771–776. doi:10.1056/NEJM199409223311204
Sanner K, Conner P, Bergfeldt K, Dickman P, Sundfeldt K, Bergh T, Hagenfeldt K, Janson PO, Nilsson S, Persson I (2009) Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril 91(4):1152–1158. doi:10.1016/j.fertnstert.2008.01.073
Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG (1996) Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 65(1):13–18
Parazzini F, Negri E, La Vecchia C, Moroni S, Polatti A, Chiaffarino F, Surace M, Ricci E (1998) Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 68(3):226–228. doi:10.1006/gyno.1997.4928
Goldberg GL, Runowicz CD (1992) Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation–is there a link? Am J Obstet Gynecol 166(3):853–854. pii: 0002-9378(92)91348-E
van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, Laven JS, Jansen CA, Helmerhorst FM, Cohlen BJ, Willemsen WN, Smeenk JM, Simons AH, van der Veen F, Evers JL, van Dop PA, Macklon NS, Burger CW (2011) Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 26(12):3456–3465. doi:10.1093/humrep/der322
Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN (1998) Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril 70(6):1049–1055. pii: S0015028298003379
Parazzini F, Negri E, La Vecchia C, Moroni S, Franceschi S, Crosignani PG (1997) Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod 12(10):2159–2161
Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN (1997) Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 67(6):1005–1012. pii: S0015028297814318
Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL (2002) Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 17(8):2209–2213
Kurta ML, Moysich KB, Weissfeld JL, Youk AO, Bunker CH, Edwards RP, Modugno F, Ness RB, Diergaarde B (2012) Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study. Cancer Epidemiol Biomarkers Prev 21(8):1282–1292. doi:10.1158/1055-9965.EPI-12-0426
Liat LG, Jaron R, Liraz O, Tzvia B, Shlomo M, Bruno L (2012) Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up. Gynecol Endocrinol 28(10):809–814. doi:10.3109/09513590.2012.671391
Cusido M, Fabregas R, Pere BS, Escayola C, Barri PN (2007) Ovulation induction treatment and risk of borderline ovarian tumors. Gynecol Endocrinol 23(7):373–376. doi:10.1080/09513590701350341
Jensen A, Jensen A, Sharif H, Sharif H, Frederiksen K, Frederiksen K (2009) Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ British Medical
Kashyap S, Moher D, Fung MF, Rosenwaks Z (2004) Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 103(4):785–794. doi:10.1097/01.AOG.0000119226.39514.1d
Conflict of interest
All authors disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within 24 months of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work.
Author information
Authors and Affiliations
Corresponding author
Additional information
S. Schüler and M. Ponnath contributed equally to this work.
Rights and permissions
About this article
Cite this article
Schüler, S., Ponnath, M., Engel, J. et al. Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet 287, 1187–1204 (2013). https://doi.org/10.1007/s00404-013-2784-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-013-2784-1